摘要
目的探讨多西紫杉醇联合卡培他滨治疗晚期胃癌的临床疗效及安全性。方法选取江油市九〇三医院2013年2月—2016年8月收治的晚期胃癌患者100例,随机分为单药组与联合组,每组50例。单药组患者采用多西他赛化疗,联合组患者采用卡培他滨联合多西他赛化疗,均以21 d为1个化疗周期。化疗2个疗程后,比较两组患者的临床疗效、毒副反应、化疗后2年生存率。结果联合组患者临床有效率高于单药组(P<0.05)。两组患者毒副反应发生情况比较,差异无统计学意义(P>0.05)。联合组患者化疗后2年生存率高于单药组(P<0.05)。结论卡培他滨联合多西紫杉醇治疗晚期胃癌的临床疗效确切,可延长患者生存期,且安全性高。
Objective To evaluate the clinical efficacy and the safety of capecitabine combined with docetaxel in the treatment of advanced gastric cancer.Methods A total of 100 cases of patients with advanced gastric cancer were selected from February 2013 to August 2016 in Jiangyou 903 Hospital,which were randomly divided into single drug group and combined group,50 cases in each group.The single drug group was treated with docetaxel chemotherapy,combined group was treated with capecitabine combined with docetaxel,21 days as a chemotherapy course.After 2 chemotherapy courses,the clinical effect,toxic and side effects were compared between the two groups,and the 2 years of survival rate was compared between the two groups.Results The clinical effective rate in combined group was higher than control group（P〈0.05）.No significant difference of toxic and side effects rate between the two groups（P〉0.05）.The 2 years of survival rate in combined group was higher than control group（P〈0.05）.Conclusion The capecitabine combined with docetaxel have an exactly clinical effect in the treatment of advanced gastric cancer,it can prolong the prognosis of patients,and with higher safety.
作者
何军
叶锐剑
何兰
HE Jun;YE Rui-jian;HE Lan(Department of Oncology, Jiangyou 903 Hospital, Jiangyou 621700, China)
出处
《临床合理用药杂志》
2018年第12期11-12,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
胃肿瘤
晚期
化疗
治疗结果
安全性
Stomach neoplasms
Advanced
Chemotherapy
Treatment outcome
Safety
